Расширенный поиск


Полный текст:


Рассматриваются схемы лечения метастатического рака мочевого пузыря (РМП), приводятся данные исследований эффективности применения различных схем и режимов химиотерапии пациентов с РМП.

Об авторах

И. Г. Русаков
Медико-санитарная часть № 60 Департамента здравоохранения г. Москвы

М. П. Головащенко
МНИОИ им. П.А. Герцена

Список литературы

1. Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581–92.

2. Vaidya A., Soloway M.S., Hawke C. et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol 2001;165(1):47–50.

3. Stein J.P., Skinner D.G. Radical cystectomy for invasive bladder cancer: long-term results ofa standard procedure. World J Urol 2006;24(3):296–304.

4. Dalbagni G., Genega E., Hashibe M. et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165(4):1111–6.

5. Cohen S.M., Goel A., Phillips J. et al. The role of perioperative chemotherapy in the treatment of urothelial cancer. Oncologist 2006;11(6):630–40.

6. Sylvester R., Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000;11(7):851–6.

7. Sternberg C.N. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Semin Oncol 2007;34(2):122–8.

8. Sternberg C.N., Yagoda A., Scher H.I. et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64(12):2448–58.

9. Harker W., Meyers F.J., Freiha F.S. et al. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 1985;3(11):1463–70.

10. Sternberg C.N., Yagoda A., Scher H.I. et al. Preliminary results of M–VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133(3):403–7.

11. Von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Semin Oncol 2002; 29(1 Suppl 3):3–14.

12. Stein J.P. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol 2003;169(1):116–7. 13. Logothetis C.J., Dexeus F.H., Finn L. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050–5.

13. Herr H.W., Bajorin D.F., Scher H.I. Neoadjuvant chemotherapy and bladdersparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16(4):1298–301.

14. Tsukamoto T., Kitamura H., Takahashi A. et al. Treatment of invasive bladder cancer: lessons from the past and perspective for the future. Jpn J Clin Oncol 2004; 34(6):295–306.

15. Skinner D.G., Daniels J.R., Russell C.A. et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145(3):459–64.

16. Sternberg C.N., de Mulder P.H., Schornagel J.H. et al. Randomized phase III trial of high-dose-intensity MVAC chemotherapy and recombinant human G-CSF versus classic MVAC in advanced urothelial tract tumors: EORTC Protocol no. 30924. J Clin Oncol 2001;19:2638–46.

17. Pollera C.F., Ceribelli A., Crecco M. et al. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs 1994;12(2):111–9.

18. Stadler W.M., Kuzel T.M., Roth B. et al. Phase II study of single–agent gemcitabine in previously untreated patients with metastatic urothelial cancer. Eur J Cancer 1997;33 Suppl 1:23–6.

19. Moore M.J., Tannock I.F.. Ernst D.S. et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15(12):3441–5.

20. Kaufman D., Stadler W., Carducci M. et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCQ: final results of a phase II study. Proc Am Soc Clin Oncol). J Clin Oncol 2000;18(9):1921–7.

21. Von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77.

22. Castagneto B., Zai S., Marenco D. et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 2004;67(1):27–32.

23. Kaufman D.S., Carducci M.A., Kuzel T.M. et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 2004; 22(5):393–7.

24. Albers P., Siener R., Härtlein M. et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma — prognostic factors for response and improvement of quality of life. Onkologie 2002;25(1):47–52.

25. Friedland D.M., Dakhil S., Hollen C. et al. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Cancer Invest 2004;22(3):374–82.

26. Guardino A.E., Srinivas S. Gemcitabine and paclitaxel as line chemotherapy for advanced urothelial malignancies. ASCO 2002. Abstr. 2413.

27. Dreicer R., Manola J., Roth B.J. et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000; 18(5):1058–61.

28. Shelley M.D., Cleves A., Wilt T.J. et al. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. BJU Int 2011;108(2):168–79.

Для цитирования:

Русаков И.Г., Головащенко М.П. ХИМИОТЕРАПИЯ МЫШЕЧНО-ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯ. Онкоурология. 2011;7(3):90-94.

For citation:

Rusakov I.G., Golovashenko M.P. CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER. Cancer Urology. 2011;7(3):90-94. (In Russ.)

Просмотров: 370

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)